STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio Pharma (BBIO) director sells stock, exercises options and receives RSUs

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma director Jennifer E. Cook reported a mix of option exercises, stock grants, and open-market sales of common stock. On June 24, 2026, she sold 37,167 shares at $70.00 and exercised options for 17,167 shares at $16.75 and 20,000 shares at $8.45 per share. Additional sales of 2,196 shares at $68.57 occurred on June 23, 2026. She also received 3,990 restricted stock units and a stock option for 5,277 shares at $68.92 on June 22, 2026. Following these transactions, she directly holds 8,383 shares of common stock. At least one sale was made under a pre-arranged Rule 10b5-1 trading plan, and the new RSUs and options generally vest in full on June 22, 2027, subject to continued board service.

Positive

  • None.

Negative

  • None.
Insider Cook Jennifer E.
Role null
Sold 39,363 shs ($2.75M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 20,000 $0.00 --
Exercise Stock Option (Right to Buy) 17,167 $0.00 --
Exercise Common Stock 20,000 $8.45 $169K
Exercise Common Stock 17,167 $16.75 $288K
Sale Common Stock 37,167 $70.00 $2.60M
Sale Common Stock 2,196 $68.57 $151K
Grant/Award Stock Option (Right to Buy) 5,277 $0.00 --
Grant/Award Common Stock 3,990 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 19,000 shares (Direct, null); Common Stock — 28,383 shares (Direct, null)
Footnotes (1)
  1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Sale at $70.00 37,167 shares at $70.00 Open-market sale of common stock on June 24, 2026
Sale at $68.57 2,196 shares at $68.57 Open-market sale of common stock on June 23, 2026
Option exercise at $16.75 17,167 shares at $16.75 Exercise of stock options into common stock on June 24, 2026
Option exercise at $8.45 20,000 shares at $8.45 Exercise of stock options into common stock on June 24, 2026
RSU grant 3,990 RSUs Restricted stock units granted on June 22, 2026, vesting June 22, 2027
Option grant at $68.92 5,277 options at $68.92 Stock option granted on June 22, 2026, vesting June 22, 2027
Shares held after transactions 8,383 shares Direct common stock ownership after all reported transactions
restricted stock units ("RSUs") financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Rule 10b5-1 sales plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan financial
"under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cook Jennifer E.
(Last)(First)(Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CALIFORNIA 94304
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026A(1)3,990A$0(2)10,579D
Common Stock06/23/2026S(3)2,196D$68.578,383D
Common Stock06/24/2026M(3)20,000A$8.4528,383D
Common Stock06/24/2026M(3)17,167A$16.7545,550D
Common Stock06/24/2026S(3)37,167D$708,383D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$68.9206/22/2026A5,277 (4)06/21/2036Common Stock5,277$05,277D
Stock Option (Right to Buy)$8.4506/24/2026M(3)20,000 (5)06/22/2032Common Stock20,000$019,000D
Stock Option (Right to Buy)$16.7506/24/2026M(3)17,167 (6)06/21/2033Common Stock17,167$017,167D
Explanation of Responses:
1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
4. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
5. 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
6. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Remarks:
/s/ Will Solis, Attorney-in-Fact06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did BridgeBio Pharma (BBIO) director Jennifer Cook do in this Form 4?

Jennifer E. Cook reported option exercises, new equity awards, and open-market stock sales. She exercised options for 37,167 shares, sold 39,363 shares in total, received 3,990 RSUs, and was granted options on 5,277 shares, ending with 8,383 shares held directly.

How many BridgeBio Pharma (BBIO) shares did Jennifer Cook sell and at what prices?

She sold 37,167 shares at $70.00 per share and 2,196 shares at $68.57 per share. These were reported as open-market sales of common stock, with at least one transaction executed under a pre-arranged Rule 10b5-1 trading plan.

What stock options did Jennifer Cook exercise in this BridgeBio Pharma (BBIO) filing?

Cook exercised options to acquire 17,167 shares at $16.75 per share and 20,000 shares at $8.45 per share. These exercises converted previously granted options into BridgeBio common stock as part of her existing equity compensation.

What new equity awards did Jennifer Cook receive from BridgeBio Pharma (BBIO)?

She received 3,990 restricted stock units (RSUs) and a stock option covering 5,277 shares at $68.92 per share. The RSUs and the new option are scheduled to vest in full on June 22, 2027, subject to her continued service on the board.

How many BridgeBio Pharma (BBIO) shares does Jennifer Cook hold after these transactions?

After the reported sales, option exercises, and grants, Jennifer E. Cook directly holds 8,383 shares of BridgeBio Pharma common stock. This figure reflects her direct ownership position following all transactions disclosed in this Form 4.

Were Jennifer Cook’s BridgeBio Pharma (BBIO) stock sales pre-planned?

At least one sale was executed under a Rule 10b5-1 sales plan adopted on March 16, 2026. Such plans allow insiders to schedule trades in advance, helping separate trading timing from day-to-day information they may receive.